Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 6, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- AVLAYAH launch generated $3.6M Q2 net product revenue; projected Q3 revenue of $10.0M-$12.0M signals rapid commercial ramp
- Coverage expanded to more than 50% of covered lives and 14 Medicaid programs, supporting near-term prescription growth
- July PRV sale added $195M gross proceeds, lifting pro forma cash, equivalents and securities above $1.1B
- Net loss widened to $127.6M from $124.1M despite R&D declining to $97.0M; launch staffing increased SG&A to $36.3M
- DNL593 results shifted to 2027, while two Alzheimer’s programs entered clinical development and DNL151 Parkinson’s development was discontinued outside genetic carriers
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.